Search research articles
Contact Us
Filters
Showing results (181-190 of 248) with videos related to
Page
of 25
Sort By:
Cancer Chemotherapy and Pharmacology
|
January 15, 2013
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer
Emmanuel S Antonarakis, Elisabeth I Heath, Edwin M Posadas, et al.
Journal for Immunotherapy of Cancer
|
May 16, 2014
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study
Shailender Bhatia, Brendan Curti, Marc S Ernstoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2016
A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy
Rana R McKay, Amado J Zurita, Lillian Werner, et al.
Clinical Genitourinary Cancer
|
May 16, 2019
Prostate Cancer National Summit's Call to Action
Elisabeth I Heath, David M Nanus, Susan Slovin, et al.
Cancer Research Communications
|
June 10, 2024
Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate-Resistant Prostate Cancer
Elisabeth I Heath, Archana Thakur, Wei Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 21, 2026
B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities Across Prostate Cancer Patient Groups
Allison Makovec, Ava P Gustafson, Nishant Gandhi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 12, 2017
A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies
Dejan Juric, Johann S de Bono, Patricia M LoRusso, et al.
The Lancet. Oncology
|
September 14, 2019
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial
Paul G Corn, Elisabeth I Heath, Amado Zurita, et al.
NPJ Digital Medicine
|
June 30, 2026
Structured reasoning failures compromise LLM interpretation of clinical oncology notes
Matthew W Kenaston, Umair Ayub, Mihir Parmar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2010
Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas
Monica M Mita, Matthew A Spear, Lorrin K Yee, et al.
Page
of 25
Search research articles
Search
Showing results (181-190 of 248) with videos related to
Sort By:
Page
of 25
Cancer Chemotherapy and Pharmacology
|
January 15, 2013
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer
Emmanuel S Antonarakis, Elisabeth I Heath, Edwin M Posadas, et al.
Journal for Immunotherapy of Cancer
|
May 16, 2014
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study
Shailender Bhatia, Brendan Curti, Marc S Ernstoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2016
A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy
Rana R McKay, Amado J Zurita, Lillian Werner, et al.
Clinical Genitourinary Cancer
|
May 16, 2019
Prostate Cancer National Summit's Call to Action
Elisabeth I Heath, David M Nanus, Susan Slovin, et al.
Cancer Research Communications
|
June 10, 2024
Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate-Resistant Prostate Cancer
Elisabeth I Heath, Archana Thakur, Wei Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 21, 2026
B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities Across Prostate Cancer Patient Groups
Allison Makovec, Ava P Gustafson, Nishant Gandhi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 12, 2017
A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies
Dejan Juric, Johann S de Bono, Patricia M LoRusso, et al.
The Lancet. Oncology
|
September 14, 2019
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial
Paul G Corn, Elisabeth I Heath, Amado Zurita, et al.
NPJ Digital Medicine
|
June 30, 2026
Structured reasoning failures compromise LLM interpretation of clinical oncology notes
Matthew W Kenaston, Umair Ayub, Mihir Parmar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2010
Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas
Monica M Mita, Matthew A Spear, Lorrin K Yee, et al.
Page
of 25